サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：バイオイメージング技術の世界市場-2022-2029
市場調査レポート
商品コード
1169017

バイオイメージング技術の世界市場-2022-2029

Global Bio-Imaging Technologies Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
バイオイメージング技術の世界市場-2022-2029
出版日: 2022年12月08日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

バイオイメージング技術の世界市場規模は、予測期間（2022-2029年）においてCAGR4.6％で成長するとされています。

バイオイメージング技術は、生物学的プロセスの非侵襲的な可視化を実現する手法です。イメージング目的には、いくつかの技術を使用することができます。これらの技術は、生命プロセスへの干渉を可能な限り抑え、物理的な干渉なしにサンプルの3D構造に関するデータを提供します。

市場力学

バイオイメージング技術の世界市場を牽引する主な要因は、慢性疾患の増加、研究開発と臨床試験の立ち上がり、技術の進歩です。新製品発表の増加は、バイオイメージング技術市場の成長に寄与しています。

研究開発への投資と進歩の増加、新製品の発売の増加が、市場の成長を促進すると予想されます。

神経変性疾患やがんなどの様々な慢性疾患の診断、予防、治療にこれらのバイオイメージング技術製品が採用され、新規製品の発売が増加していることがバイオイメージング技術市場の原動力となっています。また、がんの発生率の増加も市場の成長を後押ししています。多くのヘルスケア企業が新製品を開発するために研究開発活動を活発化させています。

バイオイメージング技術は、様々な疾患において診断、予防、治療の目的で使用されています。症例数の増加により、これらの技術の応用市場は世界的に拡大しています。さらに、主要企業による技術的に高度な製品の提供も、市場の成長に重要な役割を果たすと予想されます。

様々な新規製品の発売、規制当局の承認、調査研究などが市場の成長に寄与しています。例えば、2022年8月3日、アボットは、新規の光コヒーレンス・トモグラフィー画像化プラットフォーム（OCT）「Ultreon Software powered」が米国食品医薬品局から認可を取得したと発表しました。本製品は、人工知能（AI）とOCTを組み合わせ、冠動脈の血流、閉塞状況を高度かつ包括的に表示し、医師の意思決定を支援し、最適な治療経路を提供する革新的なイメージングソフトウェアです。

バイオイメージング技術に関連する高コストは、市場の成長を妨げると予想されます。

しかし、これらのバイオイメージング技術の高コストが、市場の成長を抑制する主要因となっています。その他の制約としては、長期的には遺伝子障害につながる可能性のある高線量照射が挙げられます。

一般に放射線量は所望の標的放射線で調整されるが、それでもがんを誘発する可能性があります。プローブや色素の添加は、脂質ベシクルの特性に干渉し、データの不正確な解釈をもたらす実験的アーチファクトを引き起こす可能性があります。

COVID-19インパクト分析

パンデミックは、世界の金融への期待、業務、危機対応戦略にプラスの影響を及ぼしています。COVID-19の発生は、ヘルスケア産業に深刻な影響を与えました。バイオイメージング技術市場は、COVIDによって莫大な利益を経験しました。様々な研究・診断センターがスタートし、COVIDとその診断例の増加によってこれらの技術に対する需要が高まったからです。複数のイニシアチブ、製品の発売、革新、コラボレーション、および合併が世界中で起こっており、市場の成長を後押ししています。例えば、2022年6月14日、MindrayはEuroanaesthesia 2022で新規のTEX20シリーズ超音波システムの発売を発表しました。このシステムは、高い画像の鮮明さ、患者中心の情報ソリューション、インテリジェントなツール、熟考されたデザインによる臨床志向のワークフローを提供するため、従来のシステムよりも機能が向上しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 臨床試験数の増加
      • 技術的進歩の高まり
    • 抑制要因
      • バイオイメージングのコスト高
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 技術タイプ別

  • ナノバイオイメージング
  • 光学イメージング
  • ポジトロンCT（陽電子放射断層撮影
  • 磁気共鳴イメージング
  • 超音波イメージング
  • コンピュータ断層撮影
  • 放射線画像診断
  • 蛍光バイオイメージング
  • その他

第8章 アプリケーション別

  • メディカルバイオイメージング
  • 分子バイオイメージング

第9章 エンドユーザー別

  • 病院
  • 診断センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • GE Healthcare
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Abbott Laboratories
  • Hitachi Medical Corporation
  • Bayer AG
  • Esaote S.p.A
  • Clario
  • Digirad Corporation
  • Bracco
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Hologic Inc.
  • FONAR Corporation

第13章 バイオイメージング技術の世界市場-DataM

目次
Product Code: DMMI1228

Market Overview

The global bio-imaging technologies market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4.6% during the forecast period (2022-2029).

Bio-imaging technologies are the methods that provide non-invasive visualization of biological processes. Several technologies can be used for imaging purposes. These technologies interfere with the life processes as minimally as possible and provide data on the 3D structure of the sample without any physical interference.

Market Dynamics

The major factors driving the global bio-imaging technologies market are increased chronic disorders, rising research and development and clinical trials, and technological advancements. An increase in novel product launches contributes to the growth of the bio-imaging technologies market.

The increasing investment and advancements in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these bio-imaging technologies products for the diagnosis, prevention, or treatment of various chronic disorders, such as neurodegenerative disorders and cancer, and the rising number of novel product launches drive the bio-imaging technologies market. An increase in the incidence of carcinomas is also aiding market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Bio-imaging technologies are used in various diseases for diagnostic, preventive, or treatment purposes. The market for the applications of these technologies is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals, and research studies contribute to the market's growth. For instance, in August 3, 2022, Abbott announced that its novel optical coherence tomography imaging platform (OCT), Ultreon Software powered, had received clearance from the U.S. Food and Drugs Administration. This is an innovative imaging software that combines artificial intelligence (AI) with OCT to provide high and comprehensive coronary blood flow, and blockages view to physicians to assist their decision-making and offer the best pathway of treatment.

The high cost associated with bio-imaging technologies is expected to hamper the market's growth.

However, the high cost of these bio-imaging technologies is the leading factor restraining the market's growth. Other limitations include high radiation dose delivery that can lead to genetic disorders in the long term.

The radiation dose is generally adjusted at the desired target radiation but can still induce cancer. The probes and dye addition interferes with lipid vesicle properties and can cause experimental artifacts that result in an inaccurate interpretation of data.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations, and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The bio-imaging technologies market has experienced huge profits due to COVID, as various research and diagnostic centers started and demand for these technologies rose due to the increasing cases of COVID and its diagnosis. Multiple initiatives, product launches, innovations, collaborations, and mergers are happening worldwide, boosting the market's growth. For instance, in June 14, 2022, Mindray announced the launch of its novel TEX20 Series ultrasound system at the Euroanaesthesia 2022. This system has improved features than its predecessors as it provides high image clarity, patient-centered information solution, intelligent tools, and clinical-oriented workflow with thoughtful design.

Segment Analysis

The nano bio-imaging segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nano bio-imaging segment is the highest market holder in the global bio-imaging technologies market. The global bio-imaging technologies market is segmented based on technology type: nano bio-imaging, optical imaging, Positron Emission Tomography, magnetic resonance imaging, ultrasound imaging, computed tomography, radiological imaging, and others. The nano bio-imaging segment is the largest market shareholder due to its better efficacy and results, advantages over other technologies, and rising advancements and adoption of these bio-imaging technologies.

Nanotechnology can solve the high-resolution image construction barrier. Nanotechnology can take Positron Emission Tomography advancements to the next level as it can maximize the resolution in currently available techniques. Nano bio-imaging can increase the target imaging specificity with the help of uniquely designed nano constructs. In medical and Fluorescence Bioimaging research, the enhanced role of nanomaterials reflects nanotechnology's impact in bioimaging. The nano bio-imaging technique or combination of imaging and nanoparticle, most importantly, provides improved contrast images. Various biocompatible nanocrystals and small molecule contrast agents can offer strong imaging signals.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in September 12, 2022, Clario explored neuroimaging or neuromelanin MRI and Opal sensor tech can be beneficial as it improves the precision and quality of the clinical outcome measures hence, characterizing the digital endpoints for decentralized clinical trials at the International Congress of Parkinson's Disease and Movement Disorders 2022.

Geographical Analysis

North America holds the largest market share in the global bio-imaging technologies market.

North America dominates the global bio-imaging technologies market, primarily due to its large population, excellent medical infrastructure, and rising number of chronic disorders. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will appear in the United States. About 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing number of brain health issues, cardiovascular disorders, and cancer cases boost the demand for bio-imaging technologies.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of applications of bio-imaging technologies in the diagnosis and examination of several diseases, providing the database of the physiology of the human body for further studies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the Bio-Imaging Technologies market.

Moreover, the growing number of product launches is responsible for the market's growth. Many vital developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in May 28, 2021, Mindray, medical devices and solutions developer and provider, launched its novel general imaging, cardiology, and women's healthcare ultrasound solutions. This is developed to increase the diagnostic evidence strength for ensuring improved patient care.

Competitive Landscape

The bio-imaging technologies market is highly competitive with local and global companies' presence. GE Healthcare, Abbott Laboratories, Hitachi Medical Corporation, Bayer AG, Esaote S.p.A, Clario, Digirad Corporation, Bracco, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic Inc., FONAR Corporation, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 31, 2021, FONAR Corporation, an MR Scanning investor, announced its acquisition of a Yonkers, New York-based Stand-Up MRI facility from where Health Management Company of America, FONAR's diagnostic imaging management subsidiary will offer non-medical management services for MRI of New York.

GE Healthcare.

Overview: GE HealthCare is a subsidiary of General Electric, an American multinational conglomerate integrated into New York, founded in 1994 and headquartered in Chicago, Illinois. It manufactures and distributes various diagnostic imaging agents and radiopharmaceuticals that can be used for imaging modalities in some procedures, such as medical imaging.

Product Portfolio:

SIGNA MR: Signa is the MR product that increases the capabilities of magnetic resonance imaging with efficient productivity and workflow solutions for scanning and offers innovations to advanced clinical procedures.

Key Developments: In Oct 2022, GE Healthcare introduced Omni Legend at the annual European Nuclear Medicine Associations meeting. This system is first on its all-novel and digital PET/CT platform as it features the latest, crystal-size digital BGO detector material category capable of providing two times more sensitivity than prior digital scanners.

The global bio-imaging technologies market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing number of clinical trials
      • 4.1.1.2. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of bio-imaging
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Technology Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 7.1.2. Market Attractiveness Index, By Technology Type
  • 7.2. Nano-Bio Imaging *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Optical Imaging
  • 7.4. Positron Emission Tomography
  • 7.5. Magnetic Resonance Imaging
  • 7.6. Ultrasound Imaging
  • 7.7. Computed Tomography
  • 7.8. Radiological Imaging
  • 7.9. Fluorescence Bioimaging
  • 7.10. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Medical Bio-Imaging *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Molecular Bio-Imaging

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. GE Healthcare *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. Hitachi Medical Corporation
  • 12.4. Bayer AG
  • 12.5. Esaote S.p.A
  • 12.6. Clario
  • 12.7. Digirad Corporation
  • 12.8. Bracco
  • 12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 12.10. Hologic Inc.
  • 12.11. FONAR Corporation

LIST NOT EXHAUSTIVE

13. Global Bio-Imaging Technologies Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and End-User
  • 13.3. Contact Us